Immunoadsorption and plasmapheresis at the ICU – A description of the frequencies and indications in a single center experience and a case report. (5th December 2022)

• Record Type: Journal Article
• Authors: Koball, Sebastian; Rogge, Johannes; Frimmel, Silvius; Hinz, Michael; Mitzner, Steffen
• Is Part Of: Therapeutic apheresis and dialysis. Volume 26(2022)Supplement 1
• Page Start: 97
• Page End: 101
• Publication Date: 2022-12-05
• Subjects: granulomatosis with polyangiitis -- immuno adsorption -- intensive care; Hemapheresis -- Periodicals; Dialysis -- Periodicals; Blood Component Removal -- Periodicals; Renal Dialysis -- Periodicals; Hémaphérèse -- Périodiques; Dialyse -- Périodiques; Sang -- Collecte et conservation -- Périodiques; 616
• DOI: 10.1111/1744-9987.13865
• Languages: English
• ISSNs: 1744-9979

Abstract

Abstract: Immunologically mediated diseases can lead to severe courses that have to be treated in an intensive care unit. The use of extracorporeal organ support systems (ventilation, ECMO) is common. A therapeutic principle for these diseases is the removal of disease‐causing antibodies. This can be done nonspecifically by plasmapheresis or specifically by immune adsorption. While most intensive care units have the facilities for plasmapheresis (membrane plasma filtration), immunoadsorption is much less common. Over a period of 10 years, the numbers of immunoadsorption and plasmapheresis treatments performed in a single center intensive care unit are shown according to their indication (IA: 18 Pts, 58 treatments. PA: 54 Pts, 148 treatments). A case study of a patient with granulomatosis with polyangiitis shows the successful treatment with immunoadsorption. The advantages of immunoadsorption in patients with complex coagulation disorders and a critical clinical picture in terms of SIRS and ARDS are shown.